Repoflor

Quick links to important sections

Repoflor

Selected form

Method of action: Probiotic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Repoflor

Property Description
Active Ingredient Saccharomyces boulardii
Form Capsules, Powder for oral suspension
Pharmacological Class Probiotic, Antidiarrheal microbiological agent
Common Purpose Restoration of gut health and microbial balance
Origin Natural origin (non-pathogenic yeast)

What Type of Medicine is Repoflor?

Repoflor is classified as a probiotic and an antidiarrheal microbiological agent intended for oral administration. It functions as a biotherapeutic agent, utilizing a living organism to provide beneficial effects within the host's gastrointestinal tract, distinguishing it from chemically synthesized medicines. This single-entity preparation is designed primarily to support the microbial ecology of the gut. The active ingredient is assigned an Anatomical Therapeutic Chemical (ATC) code within the category of intestinal anti-infectives and adsorbents.

Composition and Origin: The Active Role of Saccharomyces Boulardii

The sole active ingredient in Repoflor is the non-pathogenic yeast organism Saccharomyces boulardii. This organism is derived from a natural origin and is supplied as viable lyophilized yeast cells—a freeze-dried powder—contained within capsules or formulated for an oral suspension. Saccharomyces boulardii possesses the unique property of being naturally resistant to most standard antibiotics. This inherent characteristic is a key differentiating feature, allowing the preparation to maintain its effectiveness even during concurrent use with antibiotic therapy.

General Benefit: Supporting Intestinal Microflora Balance

The general purpose of Repoflor is to achieve intestinal microflora normalization and maintain stable digestive function. The active yeast provides multiple high-level actions, including supporting the barrier function of the intestinal mucosa and helping to counter the negative impact of various toxins. Saccharomyces boulardii contributes to overall gut integrity, helping to stabilize and protect the gut environment by active means. The overall benefit focuses on supporting a healthy ecological balance in the gut.

What side effects are possible with Repoflor?

Possible Side Effects and Safety Information

The safety profile of Repoflor (Saccharomyces boulardii) is documented by regulatory agencies and classifies potential effects according to frequency and physiological system. This information is based exclusively on official product characteristics summaries.


Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are classified as Common and involve the gastrointestinal system, primarily presenting as flatulence (stomach gas). Other less common effects involving the skin and immune system, such as pruritus (itching) and urticaria (hives), have been documented as Rare.


Serious Adverse Reactions

Official documents list Fungemia (the presence of the yeast in the bloodstream) and subsequent Sepsis as Very Rare but serious adverse events. Similarly, severe allergic responses such as anaphylactic reaction and shock are also classified as very rare immune system disorders. These serious events have been primarily reported in specific vulnerable patient populations.


Population-Specific Safety Constraints

The official safety information includes mandatory restrictions for specific groups due to the documented risk of fungemia:

  • Contraindicated for critically ill patients, immunocompromised individuals (e.g., those undergoing chemotherapy), and patients with a Central Venous Catheter (CVC).
  • Use during pregnancy and lactation is generally advised against as a precautionary measure due to insufficient reliable safety data.

Furthermore, the product is contraindicated for use with systemic or oral antifungal drugs, as this combination may diminish the intended effect of the live yeast component. It is also contraindicated for patients with known hypersensitivity to yeast or specific intolerances to excipients like lactose.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Repoflor (Saccharomyces boulardii) indicate a minimal acute toxicity profile. Specific, severe toxic symptoms directly resulting from acute oral ingestion of doses exceeding the usual regimen are generally not documented.

Overdose manifestations, if they occur, are typically restricted to increased minor gastrointestinal effects such as flatulence or bloating, which generally resolve upon discontinuation.

Immediate actions and management

Management in cases of overdose should be symptomatic and supportive treatment. Official labeling confirms that no specific antidote is known for this active ingredient. It is mandated to seek medical help right away if the patient develops severe or persistent symptoms, or experiences unusual clinical signs.

Population-Specific Overdose Context

A specific, serious risk is associated with the product in highly vulnerable patient groups. Fungemia (systemic fungal infection) is a very rare but severe outcome primarily reported in patients who are critically ill or immunocompromised, particularly those with a central venous catheter. This documented risk necessitates immediate medical intervention and specific management, including the cessation of the product.

Therapeutic Uses of Repoflor

Repoflor contains the probiotic yeast Saccharomyces boulardii, which is commonly used to help with addressing symptom clusters that may become intense or disruptive in contexts involving heightened systemic burden. This medicine is broadly applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations of digestive upset.

This product is considered relevant for easing symptoms associated with acute or episodic changes, primarily focusing on the management of diarrhea. The active ingredient may assist with managing symptoms related to physical discomfort in scenarios where additional management of discomfort is required. Specifically, the formulation is relevant for conditions presenting with systemic or localized discomfort, such as antibiotic-associated diarrhea (AAD) and traveler’s diarrhea.

The preparation is commonly used across these categories. The supportive symptom management provided contributes to improved comfort during periods of heightened symptoms. This supportive relief may help patients cope more steadily with symptom fluctuations.

Quick Fact: Symptomatic support for Diarrhea The product assists with maintaining functional stability when symptoms that interfere with daily functioning become noticeable.

Regulatory References

  1. Health Canada Licensed Natural Health Product Database

Eligibility and Restrictions for Use

Eligibility for Repoflor (Saccharomyces boulardii)

The official eligibility profile for Repoflor, based on regulatory documentation from agencies like the EMA and NPRA, establishes specific conditions and populations for approved use, conditional use, and absolute exclusion.

Absolute Contraindications

The medicine must not be used in the following populations, as the live yeast component poses a documented risk of systemic fungal infection (fungemia):

  • Patients with a central venous catheter (CVC).
  • Critically ill patients or those who are severely immunocompromised (e.g., due to severe illness or chemotherapy).
  • Individuals with a known hypersensitivity or allergy to yeast (Saccharomyces species).
  • Very small premature infants or those weighing less than 1 kg.

Restricted and Not-Established Use

  • Age-Related Use: Use is established in adults and children, but the medicine is not recommended for older adults due to an officially noted increased risk of fungal infection.
  • Life Stage: Safety is not established for pregnant or breastfeeding women; official guidance advises to avoid use to ensure safety in the absence of reliable data.
  • Condition-Specific Caution: Caution is advised for patients with diabetes or phenylketonuria (PKU) if using specific formulations that contain excipients such as sugar or aspartame.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation establishes that co-administration with Antifungal Medicinal Products (Systemic and Oral) is a highly restricted combination. This interaction is classified as therapeutic antagonism and is the most significant drug–drug constraint. Antifungal agents, including specific medicines such as Fluconazole, Itraconazole, and Amphotericin B, directly inhibit or inactivate the live Saccharomyces boulardii yeast, resulting in the loss of the product’s intended efficacy. Therefore, regulatory authorities classify this as a combination that must be avoided, often requiring mandatory administration separation rules.

The official profile also includes critical constraints related to administration with specific substances that compromise the organism's viability. The product must not be mixed with alcohol-containing beverages or carbonated liquids. Furthermore, contact with very hot liquids or foods (temperatures exceeding approximately 50 C or 122 F) is prohibited, as heat is documented to destroy the live yeast cells. No clinically significant pharmacokinetic interactions, such as those mediated by human metabolic enzymes or drug transporters, are documented in official regulatory labeling.

Mechanism of Action

How Repoflor Works

The mechanism of action of Repoflor (active ingredient Saccharomyces boulardii) is highly localized and multi-faceted, focusing on the stabilization of the internal environment of the gastrointestinal tract and the regulation of host cellular responses.

Toxin Inactivation and Pathogen Exclusion

The organism secretes a serine protease that enzymatically cleaves and inactivates specific bacterial toxins (e.g., C. difficile toxins) and physically prevents pathogens from adhering to the intestinal lining by acting as a decoy receptor. This action supports the maintenance of epithelial cell integrity and limits toxin-induced signaling that mediates cellular damage.

Epithelial Barrier Influence and Solute Transport Modulation

The yeast exerts an influence on host cellular function (a trophic effect) by modulating intracellular signaling. It helps preserve the architecture of Tight Junctions by inhibiting processes (e.g., Myosin Light Chain phosphorylation), thereby modulating intestinal permeability. Furthermore, it enhances the expression of key water and glucose transporters ( SGLT-1), which facilitates a net transport of water and solutes across the epithelium.

Regulation of Inflammatory and Secretory Cascades

The organism actively modulates cellular signaling by inhibiting key cascade activators. It inhibits the activation of central inflammatory mediators (like NF-kappa B) within the gut lining. Concurrently, it blocks the cAMP-mediated cascade responsible for active Cl^- secretion, thereby directly reducing the stimulus for water transport into the intestinal lumen.

Dosage and Administration Information

Official Administration Guidelines

Repoflor, containing the active ingredient Saccharomyces boulardii, is strictly intended for oral administration. It is supplied in capsule and powder for suspension forms, typically in a 250 mg unit strength. The standard regimen for adults often involves a total daily dose of 500 mg, which may be administered as two 250 mg doses taken twice daily or as a single 500 mg dose. Administration is flexible and not strictly dependent on meals.

Proper preparation is critical to ensure the viability of the live organism. The powder or the contents of a capsule must be dissolved in a liquid or mixed with semi-solid food. However, the preparation must not be mixed with very hot liquids (exceeding 50°C), iced drinks, or any alcoholic beverages, as this will inactivate the active yeast. Use is typically intended for a short-term course. For pediatric patients, the administration is generally aligned with the adult regimen, involving 1 or 2 250 mg units daily.

Specific procedural constraints exist concerning handling in high-risk settings. To mitigate the risk of airborne contamination, the capsules or sachets must not be opened or handled in the immediate vicinity of patients who have a central venous catheter. These procedural rules establish a standardized protocol for administration that ensures the product's functional integrity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Repoflor


Evidence for Use in Antibiotic-Associated Diarrhea (AAD) Prevention

Research examined the product’s use in clinical situations involving episodic or acute changes associated with antibiotic-associated diarrhea (AAD). Studies monitored key outcomes, including the incidence of diarrhea and the duration of diarrheal episodes, across both hospitalized adults and children receiving systemic antibiotic treatment. Findings from Meta-analyses often describe patterns in which numerically fewer cases of AAD were reported in groups that received Saccharomyces boulardii compared to control groups. However, some individual trials with smaller populations reported no measurable difference between the groups, illustrating that evidence quality varies across studies.


Evidence for Use in Treating Acute Diarrhea

Saccharomyces boulardii was studied for its use in clinical scenarios involving acute or disruptive episodes of diarrhea. Short-term RCTs specifically monitored outcomes reflecting daily functioning or activity level, focusing on tracking the duration of the diarrhea and observed changes in stool frequency and consistency. Studies highlight changes measured during the study period, particularly in pediatric populations where studies research describes the observed patterns in which outcomes related to physical discomfort evolved, detailing measurements such as a numerically shorter average duration of diarrhea.


Key Research Gaps and Remaining Uncertainty

Research explored the observation of Traveler’s Diarrhea incidence, where numerically fewer cases were reported in groups receiving Saccharomyces boulardii compared to placebo in some study settings. However, follow-up durations were limited across the majority of the research landscape. The available research provides limited insight into long-term outcomes or the durability of effects on gut microflora balance, meaning the evidence primarily addresses acute outcomes. Data for certain groups remain insufficient, and the evidence quality varies across studies, leading to heterogeneity which is a known research limitation.

Key Studies & References

  1. Probiotics for Prevention and Treatment of Diarrhea
  2. World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics

Frequently Asked Questions (FAQ)

Common questions about Repoflor (FAQ)

Q: What is the main difference between Repoflor and other similar treatments?

Official regulatory classification defines Repoflor as a non-pathogenic yeast probiotic, with the active ingredient being Saccharomyces boulardii. This composition makes it distinct from many other similar treatments, which primarily use various species of bacterial organisms, such as Lactobacillus or Bifidobacterium.

Q: Is Repoflor the same as the brand name 'Y'?

The active ingredient found in Repoflor, Saccharomyces boulardii lyo, is used in numerous products worldwide. It is available under various commercial brand names, such as Florastor and Bioflor, depending on the country of purchase and local regulation.

Q: Is there a generic version of Repoflor?

Since the product is typically regulated as an over-the-counter preparation, the active ingredient is widely available from multiple manufacturers. This broad availability allows for a functional generic availability of the core component under various brand names.

Q: How is Repoflor different from a traditional fiber supplement?

Repoflor is classified as a live biotherapeutic agent that relies on the active, multi-faceted mechanisms of a non-pathogenic yeast to influence the gut environment. In contrast, traditional fiber supplements provide physical bulk to the stool and primarily work by modifying gut transit time.

Q: How quickly does Repoflor start to work?

The product's mechanism is localized within the gastrointestinal tract and is not absorbed into the bloodstream. Evidence from studies indicates that the active yeast reaches its maximum presence and activity within the digestive tract within approximately three days after the initial dose.

Q: How long does Repoflor stay in your system?

The product is considered transient, meaning the yeast does not permanently colonize the digestive tract. Studies show that the active ingredient is typically eliminated from the system and is no longer detectable within about 2 to 5 days after the final dose.

Q: Are there any long-term effects of taking Repoflor?

Official information indicates that studies on the product’s safety and effects for periods longer than approximately 15 months are generally limited. Due to this lack of comprehensive data, the product is typically studied and intended for short-term use courses.

Q: Is it okay to take Repoflor every day?

According to official administration descriptions, the regimen typically involves a dose taken daily. However, the product is most commonly studied and described in official documents as being intended for short-term durations, often lasting up to four weeks.

Q: Is it normal to feel a change in bowel habits when starting Repoflor?

Changes in bowel habits may be reported by users when starting this product. Official safety information reports that common gastrointestinal effects include flatulence, bloating, and changes such as constipation or diarrhea.

Q: Does Repoflor cause headaches?

Official safety summaries and reports on adverse reactions do not list headache as a commonly reported or established side effect associated with the use of this product.

Q: Can Repoflor affect my sleep?

According to official safety summaries and lists of adverse reactions, effects on sleep or the central nervous system are not reported among the common or rare side effects associated with this product.

Q: Does Repoflor cause weight gain or loss?

Weight gain or loss is not listed among the common or officially established adverse effects for this product. While some limited research has observed weight changes in specific patient groups, this is not a documented expectation for general use.

Q: Does Repoflor contain any known allergens like gluten or lactose?

The core component of Repoflor is a yeast, Saccharomyces boulardii. Product labels indicate that some formulations may contain excipients like lactose, which is listed as a potential intolerance. Regulatory information suggests many product versions are manufactured and certified to be free of gluten.

Q: Does Repoflor interact with common vitamins or supplements?

Regulatory interaction databases do not report major contraindications or antagonistic effects between this product and common vitamins or simple nutritional supplements. Regulatory documents primarily focus on the known interaction with antifungal medicines.

Q: Can I take Repoflor if I am on blood thinning medication?

Regulatory interaction reviews generally show no known major contraindications with blood thinning medications (anticoagulants). The product's non-systemic action means it typically avoids certain metabolic interactions that involve the liver.

Q: What is the purpose of the black box warning (if any) on Repoflor?

Official regulatory documents confirm that the product is not required to carry a formal U.S. Black Box Warning. However, regulatory agencies have issued explicit safety warnings highlighting the risk of severe infection when the product is used in high-risk groups, such as critically ill patients or those who are immunocompromised.

Q: Is Repoflor available over-the-counter?

In the United States, the active ingredient in Repoflor is typically regulated as a dietary supplement that is available over-the-counter (OTC). The regulatory status can vary internationally.

Q: What is the shelf life of Repoflor?

Product information indicates that when the medicine is stored strictly according to the specified temperature and environmental conditions, the shelf life is typically listed as 24 months from the date of manufacture.

Q: Is Repoflor approved in countries outside of the US?

Products containing this active ingredient are widely available and regulated internationally. Official documents confirm that it is approved and regulated by numerous authorities, including those overseeing markets in Europe and other global regions.

How should Repoflor be stored and disposed of?

How to Store and Dispose of Repoflor?

Repoflor (containing Saccharomyces boulardii) must be stored strictly according to regulatory requirements to preserve the viability of the active ingredient.

Storage & Protection Requirement
Temperature and Environment Store in a cool, dry place. Avoid storage locations subject to excessive heat.
Packaging Keep the medicine in its original package.
Child Safety Keep all medications out of the reach of children.

Special handling precautions are required for this product. During administration, particularly to critically ill or immunocompromised patients, special care must be taken (such as wearing gloves and avoiding opening the capsules in the patient's room) to address the potential for contamination.

To dispose of unused or expired Repoflor, discard the product in accordance with current local authority regulations. Do not dispose of the medicine via household wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Repoflor found in:

A-Z Index: